HALO
Halozyme Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website alozyme.com
- Employees(FY) 393
- ISIN US40637H1095
Performance
+1.98%
1W
+16.49%
1M
+23.85%
3M
+13.13%
6M
+20.97%
YTD
+33.62%
1Y
Profile
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Investment Analysis Report: HALO
Overview
In this investment analysis report, we will delve into the financial statements of HALO, a company operating in the Health Technology sector within the Biotechnology industry. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operating cash flow...
Technical Analysis of HALO 2024-05-10
Overview:
In analyzing the technical indicators for HALO over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day Moving Average has been consistently rising, indicati...
Recent News & Updates
- 2024-05-16 14:55
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating(Investor's Business Daily)
- 2024-05-16 09:45
- 2024-05-15 21:45
- 2024-05-15 09:40
- 2024-05-10 12:39
Biotech Stocks To Watch: Halozyme Actionable Now After Earnings-Fueled Breakout(Investor's Business Daily)
- 2024-05-09 06:15
The 3 Best Biotech Stocks to Buy in May 2024(InvestorPlace)
- 2024-05-08 22:26
- 2024-05-08 18:15
The 3 Best Biotech Stocks to Buy in May 2024(Investorplace)
- 2024-05-08 15:10
- 2024-05-08 10:34
- 2024-05-08 08:30
- 2024-05-08 07:05
Q1 2024 Halozyme Therapeutics Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-05-08 03:52
- 2024-05-07 22:34
- 2024-05-07 20:30
- 2024-05-07 18:00
- 2024-05-07 17:49
- 2024-05-07 17:48
- 2024-05-07 17:25
- 2024-05-07 16:23
Halozyme Therapeutics: Q1 Earnings Snapshot(Associated Press Finance)
- 2024-05-07 16:01
- 2024-05-07 09:00
- 2024-05-07 05:25
- 2024-05-07 04:01
- 2024-05-06 09:16
- 2024-05-05 21:16
- 2024-05-03 04:17
How Novo-Catalent Deal Affects Halozyme (HALO)?(Insider Monkey)
- 2024-05-02 16:17
How Novo-Catalent Deal Affects Halozyme (HALO)?(Insidermonkey)
- 2024-04-30 10:01
- 2024-04-29 22:01
Page 1 of 8
previousnext